Cargando…
Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
International Society of Global Health
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107288/ https://www.ncbi.nlm.nih.gov/pubmed/35567581 http://dx.doi.org/10.7189/jogh.12.03023 |
| _version_ | 1784708458750148608 |
|---|---|
| author | Lo Muzio, Lorenzo Spirito, Francesca |
| author_facet | Lo Muzio, Lorenzo Spirito, Francesca |
| author_sort | Lo Muzio, Lorenzo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9107288 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | International Society of Global Health |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91072882022-05-20 Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022? Lo Muzio, Lorenzo Spirito, Francesca J Glob Health Viewpoints International Society of Global Health 2022-05-14 /pmc/articles/PMC9107288/ /pubmed/35567581 http://dx.doi.org/10.7189/jogh.12.03023 Text en Copyright © 2022 by the Journal of Global Health. All rights reserved. https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. |
| spellingShingle | Viewpoints Lo Muzio, Lorenzo Spirito, Francesca Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022? |
| title | Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022? |
| title_full | Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022? |
| title_fullStr | Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022? |
| title_full_unstemmed | Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022? |
| title_short | Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022? |
| title_sort | nasal vaccine or monoclonal therapy: which is winning weapon against sars-cov-2 variants in 2022? |
| topic | Viewpoints |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107288/ https://www.ncbi.nlm.nih.gov/pubmed/35567581 http://dx.doi.org/10.7189/jogh.12.03023 |
| work_keys_str_mv | AT lomuziolorenzo nasalvaccineormonoclonaltherapywhichiswinningweaponagainstsarscov2variantsin2022 AT spiritofrancesca nasalvaccineormonoclonaltherapywhichiswinningweaponagainstsarscov2variantsin2022 |